

ICL to acquire the activity of Evogene's Subsidiary, Lavie Bio

23 April 2025 | News

Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products



Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products

Evogene Ltd. a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's *MicroBoost AI for AG* platform.

The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions.

Lavie Bio is a recognized leader in the ag-biologicals industry with a robust pipeline of microbiome-based ag-biological products. Key assets to be transferred to ICL include Lavie Bio's core team, the BDD technology platform, the company's microbial bank and data assets, the majority of the company's development programs, and its commercial products. Additionally, ICL will acquire Evogene's *MicroBoost AI for AG* platform. Lavie Bio's existing agreements with its current partners will not be transferred to ICL and may generate future revenue for Lavie Bio's shareholders.

This transaction follows strategic investment by ICL Planet and more than two years of close collaboration between ICL and Lavie Bio, focused on developing innovative bio-stimulant solutions for row crops facing various abiotic stresses.

"Today marks a significant milestone in Lavie Bio's journey," said **Amit Noam**, CEO of Lavie Bio. "By combining our capabilities with ICL's expertise, we can further accelerate the development of groundbreaking ag-biological products that will provide innovative solutions to farmers around the world."

"This transaction reflects Evogene's ongoing strategy to unlock the value of its assets for the benefit of its shareholders," said **Ofer Haviv**, CEO of Evogene. "We are confident that the integration of Lavie Bio's activities into ICL will significantly advance the global ag-biologicals field and drive impactful innovation in agriculture."